| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 07/16/2009 | US20090180988 Id-1 and Id-2 Genes and Products as Therapeutic Targets for Treatment of Breast Cancer and Other Types of Carcinoma |
| 07/16/2009 | US20090180986 Treating unwanted ocular conditions using an ascomycin macrolactam |
| 07/16/2009 | US20090180985 Bridged carbocyclic oxime hepatitis c virus serine protease inhibitors |
| 07/16/2009 | US20090180984 Macrocyclic oximyl hepatitis c serine protease inhibitors |
| 07/16/2009 | US20090180983 Bicyclic, c5-substituted proline derivatives as inhibitors of the hepatitis c virus ns3 protease |
| 07/16/2009 | US20090180982 Vaccine immunotherapy for immune suppressed patients |
| 07/16/2009 | US20090180981 Quinoxalinyl derivatives |
| 07/16/2009 | US20090180980 Anti-Arenaviral Compunds |
| 07/16/2009 | US20090180975 Polynucleotide Fragments Of An Infectious Human Endogenous Retrovirus |
| 07/16/2009 | US20090180974 Agent For Protecting Body Cells |
| 07/16/2009 | US20090180958 Diagnostic and therapeutic agents |
| 07/16/2009 | US20090180954 Biokinetics of fast-clearing polypeptides |
| 07/16/2009 | US20090180953 Invention concerning GLP-1 and exendin |
| 07/16/2009 | US20090180952 Ligands binding the complex of urokinase-type plasminogen activator (uppa) and its receptor (upar) that inhibit downstream upar interactions: identification and use in diagnosis or therapy |
| 07/16/2009 | DE10301300B4 Verwendung von acylierten 4-Amidino- und 4-Guanidinobenzylaminen zur Inhibierung von Plasmakallikrein Use of acylated 4-amidino and 4-Guanidinobenzylaminen for the inhibition of plasma kallikrein |
| 07/16/2009 | DE102008003568A1 New insulin analogs useful for treating diabetes |
| 07/16/2009 | CA2711696A1 Therapeutic compositions for treatment of ocular inflammatory disorders |
| 07/16/2009 | CA2711606A1 Inhibitors of iap |
| 07/16/2009 | CA2711561A1 Insulin formulations for insulin release as a function of tissue glucose levels |
| 07/16/2009 | CA2711556A1 Methods and compositions for oral administration of insulin |
| 07/16/2009 | CA2711503A1 Glycoconjugation of polypeptides using oligosaccharyltransferases |
| 07/16/2009 | CA2711502A1 Clottable concentrate of platelet growth factors and preparation method thereof |
| 07/16/2009 | CA2711497A1 Diagnostic and therapeutic methods for efmr (epilepsy and mental retardation limited to females) |
| 07/16/2009 | CA2711394A1 Cadherin-11 antagonists and methods for the treatment of inflammatory joint disorders |
| 07/16/2009 | CA2711334A1 Hemagglutinin polypeptides, and reagents and methods relating thereto |
| 07/16/2009 | CA2711286A1 Methods and compositions for non-covalently enhanced receptor binding |
| 07/16/2009 | CA2711133A1 Wound healing peptides and methods of use thereof |
| 07/16/2009 | CA2711114A1 Topical compositions for the controlled delivery of proteins and peptides |
| 07/16/2009 | CA2710922A1 Isomerases, nucleic acids encoding them and methods for making and using them |
| 07/16/2009 | CA2710843A1 Stable aqueous cyclosporin compositions |
| 07/16/2009 | CA2710822A1 Use of peptides for promoting wound healing |
| 07/16/2009 | CA2710683A1 Transferases and oxidoreductases, nucleic acids encoding them and methods for making and using them |
| 07/16/2009 | CA2710664A1 Sldlr in viral hepatitis |
| 07/16/2009 | CA2710253A1 Method of treating erythropoietin hyporesponsive anemias |
| 07/16/2009 | CA2710022A1 Method of selecting soybeans with enhanced bioactivity and compositions for reducing cancer cell viability |
| 07/16/2009 | CA2709895A1 Treatment of fibroses and liver disorders |
| 07/15/2009 | EP2078758A2 Long-lasting absorption of flavonoids |
| 07/15/2009 | EP2078752A2 ALK-1 responds to TGF-beta and signals through SMAD-1 and SMAD-5 |
| 07/15/2009 | EP2078730A1 Process for obtaining a concentrate of von Willebrand factor or a complex of factor VIII/ von Willebrand factor and use of the same |
| 07/15/2009 | EP2078729A1 PPY agonists and uses thereof |
| 07/15/2009 | EP2078727A1 Mutagenesis of aspergillus fungi and identification of genes essential for growth |
| 07/15/2009 | EP2078532A1 Medical device comprising a haemostatic agent and haemostatic kit comprising the medical device |
| 07/15/2009 | EP2078531A2 Pharmaceutical compositions and methods useful for modulating angiogenesis |
| 07/15/2009 | EP2078530A1 Use of natriuretic peptides for treating angioedema syndromes |
| 07/15/2009 | EP2078529A1 Antimicrobial peptides |
| 07/15/2009 | EP2078525A2 Treatment of tuberculosis using immunomodulator compounds |
| 07/15/2009 | EP2078196A2 Assay for the detection of phosphorylated pth |
| 07/15/2009 | EP2078082A1 Recombinant human interferon-like proteins |
| 07/15/2009 | EP2078074A2 Dosing regimen of activated protein c and variants having reduced anticoagulant activity |
| 07/15/2009 | EP2078037A1 Thyrotropin releasing hormone receptor-orexin receptor hetero-dimers/-oligomers |
| 07/15/2009 | EP2078035A1 Peptides having activities of epidermal growth factor and its uses |
| 07/15/2009 | EP2077855A1 Therapeutic use of gba2 |
| 07/15/2009 | EP2077853A1 Immunophilin ligands and methods for modulating immunophilin and calcium channel activity |
| 07/15/2009 | EP2077852A1 Agent comprising g-csf for prevention and treatment of diabetic peripheral neuropathy |
| 07/15/2009 | EP2077838A2 Methods for the treatment of a related disorders and compositions therefor |
| 07/15/2009 | EP1874329B1 Blood pressure lowering protein hydrolysates |
| 07/15/2009 | EP1773868B1 Substituted prolines as inhibitors of hepatitis c virus ns3 serine protease |
| 07/15/2009 | EP1752162B1 Collagen-polyvinylpyrrolidone for the treatment of osteoarthritis |
| 07/15/2009 | EP1742961A4 Inhibition of fgf signaling |
| 07/15/2009 | EP1663287B1 Use of modified cyclosporins for the treatment of hcv disorders |
| 07/15/2009 | EP1653989B1 Anti-bacterial composition, especially for controlling gram-negative bacteria, comprising a peptide and an advantageously hydrophobic anti-bacterial agent |
| 07/15/2009 | EP1651190A4 Formulations containing an immune response modifier |
| 07/15/2009 | EP1517989B1 Method for the diagnosing of sphingolipid metabolism |
| 07/15/2009 | EP1446099B1 Injectable depot composition |
| 07/15/2009 | EP1403279B1 Protein polymer having unfold activity on higher-order structure of protein |
| 07/15/2009 | EP1395278B1 Ocular tear growth factor-like protein |
| 07/15/2009 | EP1268802B1 Beta-like glycoprotein hormone polypeptide and heterodimer |
| 07/15/2009 | EP1179012B2 Long lasting fusion peptide inhibitors of viral infection |
| 07/15/2009 | EP1141015B1 Insulin-like growth factor (igf) i mutant variants |
| 07/15/2009 | EP1075272B1 Methods for treating diabetes by inhibiting gdf-8 |
| 07/15/2009 | EP1061949B1 Cytokines and mitogens to inhibit graft-versus-host disease |
| 07/15/2009 | CN101484181A Recombinant host for producing L-asparaginase II |
| 07/15/2009 | CN101484180A CXCL13 antagonists and their use for the treatment of inflammatory diseases |
| 07/15/2009 | CN101481405A Somatostatin-dopamine chimeric analogs |
| 07/15/2009 | CN101480491A Bone collagen polypeptide composite solution for regulating intestines and preparation method thereof |
| 07/15/2009 | CN101480490A Process for obtaining a concentrate of von Willebrand factor or a complex of factor VIII/von Willebrand factor and use of the same |
| 07/15/2009 | CN101480489A Novel uses of plasmodium circumsporozoite protein in resisting proliferation and migration of tumor |
| 07/15/2009 | CN101480488A Complex immunopotentiator for grouper |
| 07/15/2009 | CN101480487A Use of tumor antigen CP1 protein for resisting colon cancer and rectal cancer, derived peptide segment and vaccine thereof |
| 07/15/2009 | CN100513570C Regulation effect of conjugated frame transport protein ABC1 |
| 07/15/2009 | CN100513565C Apoptin-associating protein |
| 07/15/2009 | CN100513563C Wt1-origin HLA-DR-binding antigen peptide |
| 07/15/2009 | CN100513548C Improved methods for binding AcmA-type protein anchor fusions to cell-wall material of micro-organisms |
| 07/15/2009 | CN100513422C Parathyroid hormone-like polypeptides |
| 07/15/2009 | CN100513386C Amide for inhibition of IL-8-induced chemiotaxis of neutrophil leucocytes |
| 07/15/2009 | CN100512879C Conjugate having cleavable linkage for use in liposome |
| 07/15/2009 | CN100512874C Cow nipple film coating protective agent and its preparing process |
| 07/14/2009 | USRE40850 Analogs of parathyroid hormone |
| 07/14/2009 | USRE40849 Miixture of N-acetylcysteine, vitamin C, and N-acetylglucosamine; cell membrane absorption; orally administered; may contain alpha-lipoic acid, silymarin, querecitin, 1-glutamine, and/or a probiotic; hepatitis, human immunodeficiency virus, cancer; gastrointestinal and respiratory system disorders |
| 07/14/2009 | US7560610 Using transgenic hypercellular nonhuman organisms as cell proliferating gene therapeutic tools |
| 07/14/2009 | US7560540 Nucleotide sequences coding B7 immune response regulatory protein selectively expressed on dendritic cells for use as therapeutic tool in targeting viral and tumor cell for destruction |
| 07/14/2009 | US7560535 Pharmacokinetics; glycosyltransferases; antibodies; immunoglobulins |
| 07/14/2009 | US7560532 Smad6 and uses thereof |
| 07/14/2009 | US7560531 Cln101 antibody compositions and methods of use alone and in combination with prostate specific antigen and other cancer markers |
| 07/14/2009 | US7560529 Method for producing catalytic antibodies (variants), antigens for immunization and nucleotide sequence |
| 07/14/2009 | US7560528 Proteins that comprise the alpha and beta subunit of FSH (Follicle stimulating hormone); makes it possible to ligate and amplify encoding pieces of DNA at the desired positions without the use of restriction enzymes which makes it possible to exclude introns |
| 07/14/2009 | US7560482 Aspartyl protease inhibitor; antimalaria agents |
| 07/14/2009 | US7560460 2-[(4-Chlorophenyl)methyl]-1-(4- {2-[(cyclopropylmethyl)-(methylsulfonyl)amino]phenyl }-piperazinyl) -4-(2-(1,2,3,4-tetrahydroisoquinolyl))butane-1,4-dione; obesity/dietietics; melanocortin receptor angonists; prophylaxis/treatment of diseases involving activation of the melanocortin recepetors (MCR) |
| 07/14/2009 | US7560444 Formulations comprising low molecular weight heparin and a therapeutic, prophylactic or diagnostic agent; improved bioavailability; side effect reduction |
| 07/14/2009 | US7560441 Modified and stabilized GDF propeptides and uses thereof |